Whitepaper: Advancements In Microbial Manufacturing Of Biopharmaceuticals

By Dr. Stefan Krahulec, Head of Technology & Innovation

This content was created by Boehringer Ingelheim BioXcellence™

This whitepaper provides an in-depth exploration of the evolution of microbial manufacturing within the biopharmaceutical industry, examining its past, present, and future. It begins by offering a historical overview, emphasizing key milestones that have shaped the field, including the groundbreaking use of recombinant DNA technology for insulin production and its significant impact on the advancement of microbial manufacturing processes.

The document also highlights Boehringer Ingelheim's pivotal contributions to microbial manufacturing, detailing the company’s expertise in the development, production, and marketing of products derived from microbial systems. A comprehensive comparison between microbial and mammalian cell culture technologies is presented, outlining the distinct advantages and challenges associated with each approach. This section underscores the versatility of microbial systems in producing a wide array of recombinant molecules, demonstrating their capacity to meet diverse biopharmaceutical needs.

Looking to the future, the paper offers insights into emerging trends in biopharmaceutical production, particularly the transformative potential of digital tools to enhance development and manufacturing processes. By embracing these advancements, the industry can optimize efficiency, improve product quality, and accelerate time-to-market, ultimately paving the way for innovative therapies and better patient outcomes.